Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New depression pill shows promise in Late-Stage trial

NCT ID NCT06941844

Symptom relief Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 7 times

Summary

This study tests an oral medication called MM120 against a placebo in adults with major depressive disorder. The trial has two parts: a 12-week blinded phase followed by a 40-week open-label extension where everyone gets MM120. The main goal is to see if MM120 reduces depression symptoms more than placebo over 6 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

149 people

The number who actually took part.

Started

Apr 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of MDD per DSM-5 2. Male or female aged 18 to 74 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration 4. MADRS Total Score ≥26 5. CGI-S Score ≥4 Exclusion Criteria: 1. Certain psychiatric disorders (other than major depressive disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine 4. Any clinically significant unstable illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder

Contacts and locations

Locations

  • Adams Clinical

    Watertown, Massachusetts, 02472, United States

  • Adams Clinical Boston

    Boston, Massachusetts, 02116, United States

  • Adams Clinical Harlem

    New York, New York, 10029, United States

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Austin Clinical Trial Partners

    Austin, Texas, 78737, United States

  • CNS, LLC (Jacksonville)

    Jacksonville, Florida, 32256, United States

  • CNS, LLC (Memphis)

    Memphis, Tennessee, 38119, United States

  • CNS, LLC (Orlando)

    Orlando, Florida, 32801, United States

  • Cedar Clinical Research

    Murray, Utah, 84020, United States

  • Cenexel HRI

    Berlin, New Jersey, 08053, United States

  • Charter Research

    Orlando, Florida, 32803, United States

  • Columbia - New York State Psychiatric Institute

    New York, New York, 10032, United States

  • Kadima Neuropsychiatry Institute

    La Jolla, California, 92037, United States

  • Memory Clinic, Inc

    Bennington, Vermont, 05201, United States

  • Mountain View Clinical Research, Inc

    Denver, Colorado, 80209, United States

  • Neuro-Behavioral Clinical Research

    Canton, Ohio, 44720, United States

  • Preferred Research Partners, Inc

    Little Rock, Arkansas, 72211, United States

  • Psychedelic Science Institute

    Santa Monica, California, 90404, United States

  • Sheppard Pratt

    Baltimore, Maryland, 21204, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Missouri

    Columbia, Missouri, 65212, United States

  • Uptown Research Institute (URI), LLC

    Chicago, Illinois, 60640, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.